title: Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence.
abstract: There is increasing recognition of the involvement of the immune signaling molecule, tumor necrosis factor (TNF), in the pathophysiology of stroke and chronic brain dysfunction. TNF plays an important role both in modulating synaptic function and in the pathogenesis of neuropathic pain. Etanercept is a recombinant therapeutic that neutralizes pathologic levels of TNF. Brain imaging has demonstrated chronic intracerebral microglial activation and neuroinflammation following stroke and other forms of acute brain injury. Activated microglia release TNF, which mediates neurotoxicity in the stroke penumbra. Recent observational studies have reported rapid and sustained improvement in chronic post-stroke neurological and cognitive dysfunction following perispinal administration of etanercept. The biological plausibility of these results is supported by independent evidence demonstrating reduction in cognitive dysfunction, neuropathic pain, and microglial activation following the use of etanercept, as well as multiple studies reporting improvement in stroke outcome and cognitive impairment following therapeutic strategies designed to inhibit TNF. The causal association between etanercept treatment and reduction in post-stroke disability satisfy all of the Bradford Hill Criteria: strength of the association; consistency; specificity; temporality; biological gradient; biological plausibility; coherence; experimental evidence; and analogy. Recognition that chronic microglial activation and pathologic TNF concentration are targets that may be therapeutically addressed for years following stroke and other forms of acute brain injury provides an exciting new direction for research and treatment.
authors.affiliation: Department of Pathology and Anatomical Sciences and Program for Neuroscience, School of Medicine and Biomedical Sciences, The State University of New York, Buffalo, NY, USA.
authors.forename: Tracey A
authors.initials: TA
authors.lastname: Ignatowski
authors.forename: Robert N
authors.initials: RN
authors.lastname: Spengler
authors.forename: Krishnan M
authors.initials: KM
authors.lastname: Dhandapani
authors.forename: Hedy
authors.initials: H
authors.lastname: Folkersma
authors.forename: Roger F
authors.initials: RF
authors.lastname: Butterworth
authors.forename: Edward
authors.initials: E
authors.lastname: Tobinick
mesh_terms: D000818:Animals; D001921:Brain / Q000187:drug effects / Q000503:physiopathology; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage*; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage*; D020521:Stroke / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D007074:Immunoglobulin G; D018696:Neuroprotective Agents; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept